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Abstract
Gastric cancer is the second most frequently diagnosed malignancy worldwide and therefore represents
a significant healthcare burden. Environmental and genetic factors are involved in the development of gastric
cancer. To date only one clear genetic predisposition has been identified involving mutations in the E-cadherin
gene. The disease phenotype in patients harbouring E-cadherin mutations appears to be specifically related to
diffuse gastric cancer. Little is known genetically about the other forms of gastric cancer. Since there is a growing
awareness about the necessity of early intervention criteria have been developed that aid the identification of
hereditary forms of gastric cancer. The aim of the current study was to identify minimal inclusion criteria so that
nuclear pedigree families can be provided with risk assessment and/or genetic testing. 
The results reveal that inclusion features described herein such as (a) gastric cancer diagnosed before 46 years
of age; (b) two gastric cancers among first degree relatives diagnosed over the age of 50 are useful in identifying
suspected hereditary gastric cancer patients. 
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Introduction
Gastric cancers represent the second most frequent
malignancy worldwide and are often diagnosed at
incurable stages [1]. Even though the frequency of gastric
cancer is declining in Western countries the global
incidence remains relatively high [2]. Currently, there is
no clear indication as to why the incidence is declining
in Western countries but it is thought that food
preservation may play an important role [3]. The causes
of stomach cancer are believed to be environmental (such
as H. pylori infection), genetic or a mixture of both [4].
Notwithstanding, evidence has emerged in recent years
that there are definite genetic predispositions to the
disease, the most notable being germline mutations in
the E-cadherin gene [5]. Mutations in this gene were first
identified in 3 Maori kindreds from New Zealand and it
was originally believed that E-cadherin mutations were
likely to be restricted to similar populations [5]. In
subsequent studies E-cadherin mutations were identified
in other populations thereby focusing attention on the 
E-cadherin gene and its role in gastric cancer [6-8].
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Notably, patients harbouring E-cadherin mutations
develop diffuse gastric cancer [9]. Thus far, no E-cadherin
mutations have been reported in patients presenting
mixed intestinal and diffuse gastric cancer suggesting an
alternative genetic predisposition. The genetic basis of
intestinal gastric cancer remains to be elucidated and
together there may be at least three genes associated
with hereditary gastric cancer. 
The identification of genetic predispositions to
gastric cancer remains a priority since knowledge about
the underlying molecular genetic basis of the disease
will allow for a better understanding of the mechanisms
giving rise to the disease and, perhaps more
importantly, allow for the identification of individuals
who are at risk of disease development. 
At a meeting of the International Gastric Cancer
Linkage Consortium a clinical definition of hereditary
diffuse gastric cancer and hereditary intestinal gastric
cancer was formulated (see a review on gastric cancer
by Oliveira et al in this volume). The criteria were
designed for all countries except those with a high
incidence of disease. 
There are two aspects of these criteria that can be
problematic in the clinical setting with respect to the
identification of familial gastric cancer patients. The first
is the difficulty in fulfilling criteria in countries where large
families and extensive pedigrees are impossible to be
identified, for whatever reason, even though the incidence
of hereditary gastric cancer may be quite high. Second,
the criteria do not take into consideration the existence
of family cancer syndromes where gastric cancer may
occur in association with an extra-gastric malignancy. 
From a clinical perspective, there is a necessity to
be able to identify hereditary stomach cancer families
with a minimum set of criteria that will provide a high
likelihood of ascertainment. The aim of this study was
to determine whether a minimum set of criteria could
be established to identify suspected hereditary gastric
cancer patients when there is restricted information
about the familial occurrence of disease. 
Patients and methods
A total of 198 gastric cancer patients comprising
three groups were enrolled in the study. 
Group A: Consisted of 60 patients affected by
gastric cancer from 28 randomly selected families with
at least three gastric cancers among first or second
degree relatives, independent of age. The total number
of gastric cancer cases identified was 105 but 45 of
them were excluded because the cancer family history
of respective first degree relatives was not available.
All families were registered in the International
Hereditary Cancer Center in Szczecin. 
Group B: This group comprised 41 patients affected
by gastric cancer from 27 randomly selected families
with two gastric cancers among first or second degree
relatives and at least one of the gastric cancers
diagnosed under the age of 50. Similar to Group A,
54 cancer cases were ascertained but 13 had to be
excluded because information on the disease in the first
degree relatives of the proband could not be retrieved. 
Group C: A total of 97 individuals diagnosed with
gastric cancer between the years 1993 and 1998
irrespective of family history were collected from the
city of Szczecin (total population of 400,000). 
The following inclusion criteria for the identification
of suspected hereditary forms of gastric cancer were
used and compared against one another for their
sensitivity and specificity: 
Inclusion feature 1: Probands diagnosed with gastric
cancer at or under the age of 45, no malignancy of
any kind in parents or siblings
Inclusion feature 2: Two gastric cancers among first
degree relatives diagnosed over the age of 50
Inclusion feature 3: A first degree relative affected
by an ”extra-gastric” malignancy at any age
Inclusion feature 4: Gastric cancer diagnosed under
the age of 46 and a first degree relative affected by an
”extra-gastric” malignancy diagnosed at any age. 
Statistical analysis
Univariate statistical analysis (Chi-squared, odds
ratio (OR)), and sensitivity and specificity of selection
were performed using the SAS and LOGIT programs. 
Results
The comparison of the four criteria was
undertaken from the three patient groups to identify
the most consistent criteria that can be employed in
the clinical setting for the identification of suspected
hereditary gastric cancer from nuclear pedigree data.
The first comparison was made between Group
A (associated with a genetic predisposition to the
disease) and the unselected cases from Group C. The
results indicate that if the inclusion feature 2 was
applied, a high degree of accuracy was matched
between the two groups. On the contrary, inclusion
feature 3 also was useful in exclusion of an inherited
predisposition to the disease. 
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In comparing Group B against Group C inclusion
feature 2 was omitted. Nevertheless, using a similar
approach, inclusion feature 1 was valuable in
identifying similar features in Group C. No other
associations were identified. 
Discussion
The recognition of features that can be used for the
identification of familial forms of gastric cancer in
situations where extensive pedigree analysis is unknown
or impossible to ascertain but the prevalence of the
disease is relatively high will aid the identification of
individuals at increased risk of developing gastric cancer. 
By using the criteria described herein and the
consequent recognition of significant odds ratios for
some of the inclusion features to identify gastric cancer
families we believe that the identification of additional
genes associated with this malignancy will be expedited. 
Of particular interest are the odds ratio values for
the inclusion features IF2 between Groups A and C and
IF1 between Groups B and C, which were relatively high
(15.29 and 10.1, respectively). Since these inclusion
features are significant we have a relatively high degree
of confidence that the reported observations are not
biased and are an accurate reflection of validity of our
approach for the identification of hereditary gastric
cancer families. Indeed, these criteria have been tested
in our outpatient clinics to successfully identify hereditary
gastric cancer. Therefore if we have families matching
IF1 or IF2 we are confident that a diagnosis of familial
gastric cancer can be made with high probability. 
At present it seems reasonable to offer an option
of annual gastroscopies to all individuals identified with
the use of our inclusion features beginning at an age
5 to 10 years younger than the youngest gastric cancer
identified within the patient’s family. Such surveillance
should only be an option and not a recommendation
because the efficiency of such management procedures
have not been rigorously determined to reduce
morbidity and/or mortality. Most probably the real value
of surveillance and of potential chemoprevention will
have to be established by studies in large cohorts of
individuals from families matching pedigree and clinical
criteria of suspected hereditary gastric cancer with
identified constitutional DNA variants associated with
genetic predispositions. 
So far, the list of such changes is very limited but
should be extended in the near future as more knowledge
is gained about the genetic factors associated with altered
gastric cancer predisposition. 
In summary, we advocate the use of our criteria of
suspected hereditary gastric cancer identified in this
report in order to: 
a. offer a gastroscopy option, 
b. create repositories of nuclear gastric cancer families
for future studies on the efficiency of surveillance
and chemoprevention protocols for individuals with
genetic predispositions to gastric cancer. 
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